Ildong Pharmaceutical

Vitamin and nutrition over-the-counter medicine brand that includes Aronamin Gold.

Rosuvastatin and ezetimibe combination for dyslipidemia; exported since 2023 through Indonesia's Kalbe Group under the Rozet brand, with an April 2026 contract expanding the partnership to eight Southeast Asian countries.

Oral small-molecule GLP-1 receptor agonist candidate for obesity and diabetes that showed up to 13.8% weight loss in Phase 1; the company is seeking a global partner before Phase 2.

Potassium-competitive acid blocker (P-CAB) candidate for gastroesophageal reflux disease in Phase 3; Ildong holds the overseas rights and is pursuing licensing and global commercialization.

Runs plants in Anseong and Cheongju and offers contract manufacturing (CMO) and API supply, with dedicated GMP facilities for anticancer drugs and antibiotics.

Signed an additional contract with the distribution subsidiary of Indonesia's Kalbe Group to supply the dyslipidemia combination Droptop to three more ASEAN countries.

Merged its drug-development subsidiary Yunovia into the parent company, bringing research staff and the new-drug pipeline back in-house; the merger took effect on June 16, 2026.

Signed a domestic distribution and co-promotion agreement with Pfizer Korea for the migraine treatment Nurtec ODT (rimegepant), with Ildong handling distribution in Korea.